IMCOR Snapshot
IMCOR Pharmaceutical is not quite the dynamic firm it once was. The company sold to the company's founders its core photodynamic therapies and changed its focus to concentrate on developing imaging agents. In 2003 it bought from Alliance Pharmaceutical a product to sell: Imagent, an ultrasound contrast agent, but it found little success with sales. The company has shut down its manufacturing operations and laid off its employees, and it is looking into ways to either license the technology, sell it, or engage in a merger. Oxford Bioscience Partners, which is controlled by IMCOR director Jonathan Fleming, owns two-thirds of the company.
